To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
OGT to Present at International Workshop on the Search for New IVD Biomarkers
Read time: Less than a minute
Oxford Gene Technology (OGT), provider of clinical genetics and diagnostic solutions to advance molecular medicine, has been invited to present at the British In Vitro Diagnostics Association (BIVDA) Trilateral Workshop: “Role and significance of in vitro diagnostics in the healthcare systems of the future”.
Hosted at the French Embassy in Berlin from June 16 - 17, the workshop will consist of a series of sessions and chaired discussions, presenting research in in-vitro diagnostics (IVD) applications. On June 17, Dr. John Anson, Vice President of Biomarker Discovery at OGT, will speak on ‘Screening for novel oncology biomarker panels using both DNA and protein microarrays’.
Dr. Anson’s presentation will explore how knowledge of the human genome and proteome can be used to design DNA and protein microarrays to screen for markers of cancers and autoimmune diseases.
Dr. Anson will also present the results from an internal study, demonstrating the ability to identify a set of biomarkers in serum samples that can distinguish between cancerous and non-cancerous prostate cells, with sensitivity and specificity levels above 90%. Such advances will lead to the generation of more accurate diagnostic tests with greater discriminatory power, offering improved patient outcomes.
Hosted at the French Embassy in Berlin from June 16 - 17, the workshop will consist of a series of sessions and chaired discussions, presenting research in in-vitro diagnostics (IVD) applications. On June 17, Dr. John Anson, Vice President of Biomarker Discovery at OGT, will speak on ‘Screening for novel oncology biomarker panels using both DNA and protein microarrays’.
Dr. Anson’s presentation will explore how knowledge of the human genome and proteome can be used to design DNA and protein microarrays to screen for markers of cancers and autoimmune diseases.
Dr. Anson will also present the results from an internal study, demonstrating the ability to identify a set of biomarkers in serum samples that can distinguish between cancerous and non-cancerous prostate cells, with sensitivity and specificity levels above 90%. Such advances will lead to the generation of more accurate diagnostic tests with greater discriminatory power, offering improved patient outcomes.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
